Flare Therapeutics
- 23/03/2023
- Series B
- $123,000,000
Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines for patients.
Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target ‘switch sites’ has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.
- Industry Biotechnology Research
- Website https://www.flaretx.com/
- LinkedIn https://www.linkedin.com/company/flare-therapeutics/
Related People
Amit RakhitFounder
Amit Rakhit is an experienced pharmaceutical and biotech executive and has led teams in developing medicines to transform medical practice across multiple therapeutic areas including oncology, neurology, rare diseases, and cardiovascular conditions. He is particularly interested in building innovative bridges between the biotech industry, health technology, and the patient community to better meet the needs of patients and their caregivers.
He is currently the President and CEO of Flare Therapeutics. His roles have most recently been in various C-suite positions helping companies build and grow from the start-up phase, IPO, and operating entities. He was most recently CEO at Sporos Bioventures. Prior to this role, Amit was President and Chief Medical Officer at Ovid Therapeutics where he joined in the start-up phase and worked with the team through the IPO and subsequent pipeline development.
Between 2011-2016, he had senior-level roles at Biogen including Head of Worldwide Medical where he led a team of approximately 800 professionals in medical activities for marketed and pipeline compounds in the disease areas of multiple sclerosis, neurodegenerative diseases, dementia, and hemophilia. He also led the global development programs for therapies in orphan and rare disorders such as dexpramipexole for ALS and Spinraza (nusinersen) for spinal muscular atrophy.
Prior to Biogen, he was with Bristol-Myers Squibb where he led an international medical team of 300+ professionals across 27 countries with a cross-therapeutic area focus that included cardiovascular, metabolics, oncology, HIV, virology, immunology, and neuroscience products.
His education includes Harvard fellowship training in Pediatric Cardiology at Boston Children's Hospital, MD from Tufts University, a BA from the University of California, Berkeley, and dual MBAs from Columbia Business School and London Business School.
Amit is an Advisor Trustee for the Liberty Science Center in Jersey City, NJ as well as an Advisory member of the Healthcare Board of the Partnership Fund for New York City. He has also been active with the Trevor Project whose aim is to support and provide resources to prevent suicide among LGBTQIA youth.